This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CONRAD STRITZLER, M.D.; LAWRENCE FRANK, M.D.

AMA Arch Derm. 1960;81(6):958-961.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

For the past two years we have been treating a group of 200 patients with severe acne with triacetyloleandomycin. Most of these have now been observed for a period of six months or more. We have made an attempt to answer the following questions:

1. Are we sure the results are due to the antibiotic rather than adjuvant topical measures, or the natural remissions of the disease?
   
2. Are we encouraging the emergence of resistant organisms, especially staphylococci?
   
3. Are there other possible sequelae to such long-term therapy with a broad-spectrum antibiotic?
   
4. How will long-term oleandomycin therapy for acne influence the response to the same antibiotic when used later in the management of systemic infection or furunculosis? Will it influence the incidence of these conditions in the treated patients?
   

Author Affiliations
Brooklyn

From the Division of Dermatology and Syphilology, Department of Medicine, College of Medicine at New York City, State University of New York, Brooklyn.

Footnotes
Submitted for publication Sept. 8, 1959.

The triacetyloleandomycin used in this study was supplied through the cooperation of Dr. Iezzoni, of Chas. Pfizer & Co., Inc., Brooklyn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?